InstilBio UK, 48 Grafton St, Manchester M13 9XX, Manchester, United Kingdom; School of Medical Sciences, The University of Manchester, Oxford Rd, Manchester, United Kingdom.
InstilBio UK, 48 Grafton St, Manchester M13 9XX, Manchester, United Kingdom.
Cancer Treat Rev. 2023 Dec;121:102632. doi: 10.1016/j.ctrv.2023.102632. Epub 2023 Oct 5.
Ovarian cancer is amongst the ten most common cancer types in women, and it is one of the leading causes of death. Despite the promising results of targeted therapies, including anti-angiogenic agents and poly (ADP-ribose) polymerase inhibitors (PARPi), the majority of patients will relapse and develop treatment resistance, implying that novel therapeutic strategies are required. Adoptive cell therapy (ACT) refers to the process by which autologous immune cells are used to eliminate cancer. Examples include tumour infiltrating lymphocytes (TILs), T cells genetically engineered with T cell receptors (TCR), or chimeric antigen receptor (CAR)-T cells. Recently, ACT has revealed promising results in the treatment of haematological malignancies, however, its application to solid tumours is still limited due to lack of functionality and persistence of T cells, prevalence of an exhausted phenotype and impaired trafficking towards the tumour microenvironment (TME). In this review we explore the potential of ACT for the treatment of ovarian cancer and strategies to overcome its principal limitations.
卵巢癌是女性中最常见的十种癌症类型之一，也是导致死亡的主要原因之一。尽管靶向治疗（包括抗血管生成剂和聚（ADP-核糖）聚合酶抑制剂（PARPi））取得了有希望的结果，但大多数患者仍会复发并产生耐药性，这意味着需要新的治疗策略。过继细胞疗法（ACT）是指利用自体免疫细胞来消除癌症的过程。例如肿瘤浸润淋巴细胞（TILs）、经过基因工程改造的带有 T 细胞受体（TCR）的 T 细胞或嵌合抗原受体（CAR）-T 细胞。最近，ACT 在治疗血液恶性肿瘤方面显示出了有希望的结果，然而，由于 T 细胞的功能和持久性缺乏、衰竭表型的流行以及向肿瘤微环境（TME）的迁移受损，其在实体瘤中的应用仍然有限。在这篇综述中，我们探讨了 ACT 治疗卵巢癌的潜力以及克服其主要限制的策略。
